Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » Ignt (Page 1)

 - UBBFriend: Email this page to someone!   This topic comprises 2 pages: 1  2   
Author Topic: Ignt
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
Today should be another good day for Ignt. Looking for good news at the close of the day.
Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
congrates to everyone who rode with ignt yesterday , they have been good to me so im going with them again today got a great feeling ,

11.8% increase yesterday

macd line was stable all week

expecting a big jump in the rsi as well as the price

by later in the morning pre buys will be going crazy

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen Technologies, Inc. develops, markets, and distributes medical technologies and products with applications in the respiratory device and medical diagnostics market primarily in the United States. It offers BAFI line of products, its flagship product, which are wireless digital low gas warning system for pressurized gas cylinders. These products include Oxyview and OxyAlert, which provides the respiratory clinicians, including pulmonologists, respiratory therapists, and patient care technicians a medical product that offers assurance and safety to home oxygen patients and hospitalized patients, while monitoring oxygen flow during oxygen therapy; and GasAlert, which monitors and detects gas flow for home appliances, such as ovens, washer, dryer, refrigerator, and outdoor plumbed barbeques. The BAFI line of products has applications in the medical industry, home consumer, residential development industry, safety and protection (fire and police), aircraft industry, and the recreational vehicle industry. The company also offers a Secure Balance product, a private-label product that includes a vestibular function testing system and balance therapy system for physicians. Ingen Technologies was founded in 1999 and is based in Yucaipa, California.
Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
ErroneousJ
Member


Rate Member
Icon 1 posted      Profile for ErroneousJ     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives.

Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors.
Ingen’s Mission: Our Commitment to Customers

Ingen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of our product.
The Beginning

Ingen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA.
Our Capabilities

We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.

Ingen Technologies, Inc. introduces Oxyview® , the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls.

Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism.

One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use.
Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,

"...it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance."
An L.A. Times article said,

Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times.

Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:

* NUTRITION AND ENERGY BOOST
While most people notice an energy boost right away, the nutritional results with undernourished people is staggering.
* DETOXIFICATION
In vitro studies show the Moringa’s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way.
* ANTIBIOTIC
Moringa works as a gentle, natural antibiotic,
See Eilert, U.,B. Wolters and A. Nahrstedt. “The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.” Journal of Medicinal Plant Research, 42, pp 55-61. 1981
* SKIN TREATMENT
And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself.
* ANTI-INFLAMMATORY
Indian traditional medicines have long used the Moringa in treating the body’s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, “Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123.
* ULCERS
The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17.
* DIABETES
An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18.
* SLEEP
The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18

In short some studies have proved Moringa leaves effective for treating,

* Blood pressure
* Diabetes
* Colitis and Diarrhea
* Used as a diuretic
* Headache
* Glandular swelling
* Skin antiseptic
* Fevers

Seeds are used for,

* Fevers
* Tumors
* Rheumatism
* Skin diseases
* Prostate and bladder issues

Leadership

Scott R. Sand




Chief Executive Officer and Chairman of the Board

Thomas J. Neavitt




Chief Financial Officer

J.R. Marple




Senior Accountant

Ron Mitchell




Certified Public Accountant

William Denney




Auditor- Child, Van Wagoner and Bradshaw LLC

Christopher A. Wirth




Chief Operations Officer & Director

Bradley C. Klearman




Director and EVP of Sales & Distribution

David Wald




Office Manager

John Finazzo, MD




Director and Chairman of the Medical Advisory Board

Stephen O’Hara, MD




Director and Member of the Medical Advisory Board

Peter Wilke




Attorney

Donn Harms




Patent Attorney

Robert H. Sand




Chief Manufacturing Engineer

Richard Campbell




Product Design & Engineering

Posts: 56 | Registered: Aug 2009  |  IP: Logged | Report this post to a Moderator
wealthy-future
Member


Rate Member
Icon 14 posted      Profile for wealthy-future     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by Chuck.w:
Today should be another good day for Ignt. Looking for good news at the close of the day.

Hoping for a jump on this one with all this good news.

--------------------
A Brighter Tomorrow

Posts: 12 | From: Florida | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT

is in a buyers market right now its a low risk with the potential to make a quick profit and with the possibility of news breaking later in the day it should start to move with a very good chance to heat up. bb's adding, next week will be big imo.

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen Brings Aboard Leading OEM Partner for Australia


Medical Industries Australia Pty LTD Signs OEM Contract

YUCAIPA, Calif., Oct 23, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.

In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.

In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.

"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

http://www.medind.com.au/Home/tabid/2059/Default.aspx

www.ingen-tech.com

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
www.info@ingen-tech.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Business Contracts

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
wealthy-future
Member


Rate Member
Icon 14 posted      Profile for wealthy-future     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by mickymoose99:
IGNT

is in a buyers market right now its a low risk with the potential to make a quick profit and with the possibility of news breaking later in the day it should start to move with a very good chance to heat up. bb's adding, next week will be big imo.

You could be right on with that statement. The news is looking good, the volume is good, let's make money.
Posts: 12 | From: Florida | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
HEY ALL IGNT HAD GREAT VOLUME ON FRI CLOSEING @ 118.4 MIL AND UP 11.7%!!! RSI LINE IS BULLISH @51.48 AND MAC D LINE IS EVEN WITH THE SIGNAL LINE AND HAS BEEN SINCE JULY!!. NEXT RESISTACE IS .0047. IMO THIS STOCK IS GOING TO HAVE GREAT VOLUME AND PRICE INCREASES THROUGHOUT THE WEEK. THIS STOCK IS ON MY RADAR AND IM LOOOKING TO MAKE A PROFIT!!!!
Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
ignt started to move friday and with news that came out friday and today with a grooss profit increase and 63% gross margin in sales that should get this moving fast. ignt is a good quick investment , should get hot through the week with more poss news at close today
Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen Reports First Quarter Sales Increase
With Gross Profits Increase and a 63% Gross Margin of Sales

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EDT, Monday October 26, 2009


YUCAIPA, Calif., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the company has reported an increase in first quarter sales for 2009 as compared to the same quarter in 2008. Gross profits represented 63% gross margins.


Ingen reported gross sales of $106,483 in the quarter ended August 31, 2009. This represented an increase from sales of $987 in the quarter ended August 31, 2008. The sales were further sparked by the introduction of an "all-in-one" Oxyview Nasal Cannula unit that includes a cannula with the Oxyview flow meter included. Additional capital also enabled the company to increase its advertising and marketing of the Oxyview products. Ingen anticipates that sales of Oxyview will increase from the current quarter's sales as the company expands its sales channels. The total cost of sales was $38,804 in the quarter ended August 31, 2009 and the gross profit was $67,679 (a gross margin of 63.6%).


"We are seeing the initial results of the introduction of our Oxyview Nasal Cannula. There is still hard work ahead of us, and our management is focused on distribution and sales. Our immediate focus being ISO certification and CE Mark requirements that we will complete in late December-2009. Between now and then we are closing distribution for export of our products, and reorganizing our domestic distribution. The home oxygen patients are the bulk of our sales at this time, and this is a good indication that they want and need this product. We expect an increased response for our new Oxyview Nasal Cannula upon its introduction to the annual Chest Physicians meeting at the end of this month, along with Medical and Arab Health conventions in the near future. Targeting these respiratory physicians, management and home oxygen suppliers will increase sales significantly," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board

Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
Pinnacle Digest: Looking For Shareholder Opinions On Ingen Technologies' Latest News

Oct 26, 2009 (M2 PRESSWIRE via COMTEX) -- www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that Medical Industries Australia has signed an OEM contract with Ingen, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Join The Ingen Investor Discussion Here: http://www.pinnacledigest.com/company/ignt

Join PinnacleDigest.com to

Find out if Ingen makes it as a Pinnacle Featured Company,

Chat with other shareholders invested in Ingen,

Explain to our investor community what differentiates this company,

Connect with investors and professionals in the equity markets,

Meet the thousands of investors who have already become members of the Pinnacle community.

PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

PinnacleDigest.com has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated PinnacleDigest.com in any form to disseminate this release.

This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.

CONTACT: Pinnacle Digest WWW: http://www.pinnacledigest.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.


(C)1994-2009 M2 COMMUNICATIONS
-0-

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen CEO Live Radio Interview Today With The Money Channel
Increased Sales, Margins and Profits Bring Bright Future for Shareholders

Press Release
Source: Ingen Technologies, Inc.
On 12:38 pm EDT, Tuesday October 27, 2009
Buzz up! Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, discussed increased profits, margins and sales at 11:34am eastern daylight time today on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"The company sales for first quarter had increased more than a 100 times compared to last year due to the acceptance of the product by the home oxygen patients and respiratory medical market. Margins of sales were slightly better than 63%. The future of this company for any investor, compared to other companies in the market place, is strong and steady," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.


The company introduced a new revolutionary product into the medical market this past June-2009, called the Oxyview Nasal Cannula. Oxyview, the World's First Patient In-Line Oxygen Flow-Meter, and Oxyview Nasal Cannula, the World's First Cannula with a built-in oxygen flow meter is another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients who require home oxygen therapy or supplemental oxygen.


http://www.moneychannel.tv/scas.php


http://www.medcoforum.com/about.php


http://www.chestnet.org/


http://www.copddigest.org/


http://todayssenior.homestead.com/


http://www.mdna.com/shows/medica.html#page=page-1


http://www.arabhealthonline.com/congress/


www.ingen-tech.com


About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.


The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472


Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.


Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180 www.info@ingen-tech.com

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
wealthy-future
Member


Rate Member
Icon 1 posted      Profile for wealthy-future     Send New Private Message       Edit/Delete Post   Reply With Quote 
Well, I just found out that I can no longer buy Ignt through scottrader? Does any one have a good penny stock broker they could tell me about?

--------------------
A Brighter Tomorrow

Posts: 12 | From: Florida | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Newbie13
Member


Rate Member
Icon 1 posted      Profile for Newbie13     Send New Private Message       Edit/Delete Post   Reply With Quote 
I use zecco and love it
Posts: 108 | From: Connecticut | Registered: Jun 2009  |  IP: Logged | Report this post to a Moderator
wealthy-future
Member


Rate Member
Icon 1 posted      Profile for wealthy-future     Send New Private Message       Edit/Delete Post   Reply With Quote 
[QUOTE]Originally posted by Newbie13:
I use zecco and love it [/QUOTE

Just opened a account. I will try this company but sad to see scottrader not doing much penny's anymore.

--------------------
A Brighter Tomorrow

Posts: 12 | From: Florida | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT
Keep an eye on it , IGNT came out with news friday after the close and this morning .
i see this getting into position to make a nice run .
its in the bearish range at 36.19
prev close was 0.0029
MacD Line is even
has the potential for a quick flip

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen CEO Live Radio Interview Tomorrow With The Money Channel
CEO Discusses Projections for 2010 of $10M in Sales

Press Release
Source: Ingen Technologies, Inc.
On 10:15 am EST, Monday November 2, 2009

YUCAIPA, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.


A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.


The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.


With proper marketing, advertising, branding, distribution and direct sales; Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December 2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.


With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.


"With the new auditors in place, and near completion of the required SEC filings, the management is focused on increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT
Starting to heat up +16%
RSI Line is @ 42.72 curving up looking good
volume is moving should go over the 10 day avg of 56 million as of now its at 55 million
bids are building .0028 as of now
staring to heat up,

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT
Its now up 20%
RSI Line up to 44.14 and rising
looking good , setting it self up
for a poss strong run

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT
congrates to all on IGNT
+ 36%
RSI Line 49.21 and still rising looks good
volume way over the 10 day avg

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT
Yesterdays open 0.0029
Close 0.0033
+ 32%
RSI Line 48.03 and rising
MacD even
Slope curving up
charts look possitive
im looking for IGNT to have another good day

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
njrep732
Member


Rate Member
Icon 1 posted      Profile for njrep732     Send New Private Message       Edit/Delete Post   Reply With Quote 
Nov 03, 2009 (M2 PRESSWIRE via COMTEX) -- Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that the CEO, Scott Sand, will discuss conservative projections for 2010 at 11:24AM today on The Money Channel's American Scene Radio with host Steve Crowley, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion

ignt had a big day yesterday, everything seemed to kick in gear in the after noon. and from reading this little piece from the article. it seems that if people tune in and get convinced it will show the same attributes as yesterdays market... so traders tune in so wats happening with our company!

Posts: 43 | From: new jersey | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT Ingen Technologies, INC.
Charts look great.
Volume from yesterday was 89,495,632.
Think stock could have another good run today.IMO
Interview with CEO Scott Sand to discuss conservative projections for 2010 on The Money Channel. Good luck to all.

Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT HAD A GREAT DAY YESTERDAY!! THIS STOCK HAD SOME GREAT VOLUME 89 MIL AT THE EOD AND THE PRICE WAS DRIVEING UP WITH A NEW HOD!! CHARTS LOOKS GOOD ON THIS STOCK. RSI LINE HEADING NORTH AND APROACHING BULLISH. MAC D LINE HAS BEEN RUNNING EVEN WITH THE SIGNAL LINE FOR A WHILE. WE BROKE THROUGH THE 20 DAY MA LINE AND .004 IS OUR NEXT RESISTANCE AND ALSO THE 50 MA. IMO THIS STOCK IS GOING TO HAVE ANOTHER GREAT DAY WITH MORE PRICE INCREASES TODAY AND THROUGHOUT THE WEEK. LOOKS LIKE A GOOD STOCK TO GET INTO AND MAKE SOME PROFITS!!! ALSO KEEEP AN EYE ON TCHH,EVRN,
Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
Wall Street News Alert: Stock on the Move: HearAtLast Holdings -- November 3, 2009

Weston, FLA, Nov 03, 2009 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning , Ingen Technologies, Inc.


Ingen Technologies, Inc. (OTC: IGNT) up 32% on 89.4 million shares traded.

On Nov 2, 2009 Ingen Technologies, Inc. recently announced that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.

A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
CEO Talks About $50M With Export Sales Projections

Press Release
Source: Ingen Technologies, Inc.
On 11:45 am EST, Tuesday November 3, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss the projected export sales of their new Oxyview Nasal Cannula this Friday, November 6, 2009 at 10:34AM Eastern Standard Time on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.0030 -0.0003


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The company's recently issued Chinese patent, new distribution and expected ISO certification in December-2009 opens doors in the People's Republic of China. Chronic obstructive pulmonary disease (COPD) is a major epidemic in China, costing that society billions of dollars in health care expenditures and lost productivity from premature (and perhaps unnecessary) deaths every year. In 2000, the total cost of COPD and other smoking-related diseases in China was more than U.S. $5 billion and, in 2000, COPD was the second leading cause of mortality in China, trailing only cerebrovascular disease. Ingen has secured intellectual property rights in China, and upon ISO Certification in December-2009, projects a staggering $25M annual sales revenue in China along by 2012. The company has received an offer for China distribution from a major supplier and this will be announced later this month.


The company's pending European patents expected to issue in 2010, its new introduction at Germany's MEDICA this November-2009 and ISO Certification and CE Mark scheduled for December-2009 triggers generous revenues in Europe starting next year. In Europe estimates suggest that 10% of the population has COPD and is now the 5th leading cause of death in the European Communities. The social healthcare structure throughout Europe and for home oxygen care would recognize the cost savings through the use of the company's Oxyview Nasal Cannula and cost reductions as a result of a decrease in unnecessary home visits. Europe's medical care system indicates at least $25M in annual sales to Ingen by 2012.


The company's ISO Certification in December 2009 also allows its new distributor in Australia, Medical Industries Australia, to begin selling the new Oxyview Nasal Cannula immediately. COPD is costing the nation an estimated $818 to $898 million annually. This is a conservative estimate because it is based on 1993-94 figures extrapolated to the Year 2001. The addition of hidden costs could increase the estimate to more than $1 billion per year. It is the 4th leading cause of death for Australians. Annual sales in Australia should reach $1M by 2012, considering their medical care structure and economy of scale.


A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.


"Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M. The export sales are expected to out-perform domestic sales here in the USA as COPD is a more serious problem in China and Europe," Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
MY LITTLE BIRD JUST FLEW BACK FROM ignt WINDOWS HE SAID POSS BIG NEWS COMING AT THE CLOSE
Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT Ingen Technologies, INC.

Stocks trading great again today. Volume up around 10day moving avg. Stocks trading like possible news coming out after close today.IMO. Good luck to all

Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ingen Announces Projections of $10M in Sales for 2010

YUCAIPA, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

http://www.moneychannel.tv/scas.php

http://www.swivel.com/data_sets/show/1016323

http://www.copd-international.com/library/statistics.htm

www.ingen-tech.com

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
njrep732
Member


Rate Member
Icon 1 posted      Profile for njrep732     Send New Private Message       Edit/Delete Post   Reply With Quote 
this company is forming big things future wise. i definatly think that this stock has what it takes to make it in the dollars imo. their has been alot of news focused on the CEO which tells me that this corp. is trying to make it up the totem pole. scott sand being a guest on the money channel is huge.. keep an eye out in tomorrows market. profiteers welcome! thanks chuck for the thread, hope everyone does great tomorrow. dont for get prfits.
Posts: 43 | From: new jersey | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
wealthy-future
Member


Rate Member
Icon 1 posted      Profile for wealthy-future     Send New Private Message       Edit/Delete Post   Reply With Quote 
Great post on the news, I will be watching tomorrow. It's looking good.

--------------------
A Brighter Tomorrow

Posts: 12 | From: Florida | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
Chuck.w
Member


Rate Member
Icon 1 posted      Profile for Chuck.w     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT Ingen Technologies, INC.

Ready for another good day from IGNT.
Yesterdays vol. 49,975,388
Closed at .0031
RSI line 45.75

News after close looked great last night.
Should be another good day for IGNT.IMO.

Posts: 149 | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
YUCAIPA, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA has resulted in an increase of buyers for Ingen's new Oxyview Nasal Cannula. The company now provides 8 different models of the Oxyview and Oxyview Nasal Cannula. The cannulas are designed for Adults, Pediatrics and Infants, and include 0-6 liters/minute and a low-flow 0-3 liters/minute unit that is either reusable or comes attached to a high quality 7' latex free oxygen tube with a curved soft-tip nasal cannula. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow rate readings for the patient and caregiver.

The company also received very good news today from the COPD Foundation. The November issue of COPD Digest has been printed and shipped and is receiving an excellent response at the American College of Chest Physician's Annual 2009 conference in San Diego, CHEST 2009. Ingen has a full-page color ad in this edition of the COPD Digest and telephone orders and PayPal orders have increased this week.

"We are seeing a strong increase in revenues, and expect this trend to continue over the next several years. Our accountants and auditors are diligently working on completion of the SEC filings, specifically the 10-KSB. We anticipate filing a revised annual and quarterly report on the OTC Pink Sheets later next week. The company is progressing forward very nicely at this time and we will continue to make public announcements as each event occurs," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
IGNT moving on the ask .
volume 64 million and is over the ten day avg
RSI LINE is the same at 44.60 but starting to show a nice curve
MACD is even
keep your eye on it , getting into good position
COULD BE LOOKING AT A NICE JUMP

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
  This topic comprises 2 pages: 1  2   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share